Literature DB >> 2863804

Risk factors for retrolental fibroplasia: experience with 3,025 premature infants. National Collaborative Study on Patent Ductus Arteriosus in Premature Infants.

D M Purohit, R C Ellison, S Zierler, O S Miettinen, A S Nadas.   

Abstract

The rate of retrolental fibroplasia in relation to prenatal and neonatal characteristics was explored on the basis of a cohort of 3,025 neonates with birth weight less than 1,750 g. The overall rate of retrolental fibroplasia of any degree at hospital discharge was 11%, varying from 43% for those with birth weight between 500 and 749 g to 3% for those in the 1,500- to 1,750-g category. Among the potential determinants, the main interest was in nonhyperoxic characteristics, conditional on measures of prematurity and oxygen supplementation. Maternal diabetes and antihistamine use during the last 2 weeks of pregnancy were associated with significantly higher rates of retrolental fibroplasia, whereas toxemia was associated with lower rates. Frequent apneic spells, bronchopulmonary dysplasia, and sepsis in the neonate were also associated with significantly higher rates. On the other hand, the data indicate no independent role of low Apgar score, intraventricular hemorrhage, exchange transfusion, patent ductus arteriosus, or certain other characteristics previously postulated as risk factors.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2863804

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  12 in total

Review 1.  Retinopathy of prematurity.

Authors:  E Bossi; F Koerner
Journal:  Intensive Care Med       Date:  1995-03       Impact factor: 17.440

Review 2.  Retinopathy of prematurity: a review of risk factors and their clinical significance.

Authors:  Sang Jin Kim; Alexander D Port; Ryan Swan; J Peter Campbell; R V Paul Chan; Michael F Chiang
Journal:  Surv Ophthalmol       Date:  2018-04-19       Impact factor: 6.048

3.  Retinopathy of prematurity and maternal age.

Authors:  Wei-Chi Wu; Frank Shih-Chang Ong; Jane Zea-Chin Kuo; Chi-Chun Lai; Ning-Chia Wang; Kuan-Jen Chen; Yih-Shiou Hwang; Tun-Lu Chen; Chia-Pang Shih
Journal:  Retina       Date:  2010-02       Impact factor: 4.256

4.  The progression of retinopathy of prematurity and fluctuation in blood gas tension.

Authors:  Y Saito; T Omoto; Y Cho; Y Hatsukawa; M Fujimura; T Takeuchi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1993-03       Impact factor: 3.117

5.  A novel model of retinopathy of prematurity in normobaric hyperoxic conditions.

Authors:  Taner Ozgurtas; Sercan Tekin; Fatih Yesildal; Umut Karaca; Fevzi Nuri Aydin; Muhammed Talha Ugurlu; Mehmet Ozler; Hakan Durukan
Journal:  Int J Ophthalmol       Date:  2016-09-18       Impact factor: 1.779

Review 6.  The development of the rat model of retinopathy of prematurity.

Authors:  Joshua M Barnett; Susan E Yanni; John S Penn
Journal:  Doc Ophthalmol       Date:  2009-07-29       Impact factor: 2.379

7.  Neurodevelopmental outcome and school performance of very-low-birth-weight infants at 8 years of age.

Authors:  A Calame; C L Fawer; V Claeys; L Arrazola; S Ducret; L Jaunin
Journal:  Eur J Pediatr       Date:  1986-12       Impact factor: 3.183

8.  Incidence and Risk Factors of Retinopathy of Prematurity among Preterm Infants in Shiraz/Iran.

Authors:  Mojgan Bayat-Mokhtari; Narjes Pishva; Abbas Attarzadeh; Hamid Hosseini; Shahnaz Pourarian
Journal:  Iran J Pediatr       Date:  2010-09       Impact factor: 0.364

9.  Retinopathy of prematurity and risk factors: a prospective cohort study.

Authors:  Padmani Karna; Jyotsna Muttineni; Linda Angell; Wilfried Karmaus
Journal:  BMC Pediatr       Date:  2005-06-28       Impact factor: 2.125

Review 10.  Association of Gestational Hypertensive Disorders with Retinopathy of prematurity: A Systematic Review and Meta-analysis.

Authors:  Priscilla Y L Chan; Shu-Min Tang; Sunny C L Au; Shi-Song Rong; Henry H W Lau; Simon T C Ko; Danny S C Ng; Li Jia Chen; Jason C S Yam
Journal:  Sci Rep       Date:  2016-08-05       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.